Special Diabetes Program Reauthorization Act of 2025
Summary
What This Bill Does
The Special Diabetes Program Reauthorization Act of 2025 is a narrow health-research and treatment-continuity bill. It amends section 330B of the Public Health Service Act to continue the Special Diabetes Program for Type I diabetes with $160 million for each of fiscal years 2026 through 2030. The funds remain available until expended. The program supports federal work on Type 1 diabetes prevention, treatment, research, and related public-health activities. The practical effect is to give NIH, HHS, diabetes researchers, clinicians, and patient communities five more fiscal years of dedicated program funding rather than letting the authority lapse.
Who Benefits and How
People with Type 1 diabetes benefit because the dedicated Special Diabetes Program funding stream is extended for five fiscal years. Diabetes researchers benefit from $160 million per year in continued program support. Pediatric diabetes clinicians benefit if research and public-health activities improve prevention, treatment, and disease-management tools. Families managing Type 1 diabetes benefit from continuity in federal research and care-improvement work.
Who Bears the Burden and How
HHS diabetes program staff must administer the extended funding through fiscal year 2030. NIH diabetes research administrators must plan around the renewed Special Diabetes Program funds. Federal taxpayers fund $160 million for each fiscal year from 2026 through 2030. Appropriations committees must account for the five-year program extension.
Key Provisions
- Extends the Special Diabetes Program for Type I diabetes through fiscal year 2030.
- Authorizes $160 million for each of fiscal years 2026 through 2030.
- Provides that the funds remain available until expended.
- Supports continued federal Type 1 diabetes research, prevention, treatment, and public-health activity.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Extends the Public Health Service Act Special Diabetes Program for Type I diabetes by authorizing $160 million for each of fiscal years 2026 through 2030, with funds remaining available until expended.
Key Policy Areas
Health Care, Diabetes, Appropriations
Primary Purpose
Extends the Public Health Service Act Special Diabetes Program for Type I diabetes by authorizing $160 million for each of fiscal years 2026 through 2030, with funds remaining available until expended.
Policy Domains
Resolution provisions
Identified Gains
Contextual inference, no direct clause citation- People with Type 1 diabetes
- Diabetes researchers
- Pediatric diabetes clinicians
- Families managing Type 1 diabetes
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- HHS diabetes program staff
- NIH diabetes research administrators
- Federal taxpayers
- Appropriations committees
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMs. DeGette (for herself, Mr. Bilirakis, and Mr. Ruiz) introduced …
Referred to the House Committee on Energy and Commerce.
Introduced in House
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology